Coming soon

Events

See what BetaGlue will attend
San Francisco - JP Morgan Health Conference

44th Annual J.P. Morgan

Healthcare Conference

January 12-15, 2026 | San Francisco, California

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development
Spectrum Miami

Advancements in the fight against cancer

Spectrum Conference

January 15-17, 2026 | Miami (FL), USA

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development
MioLive - Roma

World Congress of Interventional Oncology

MIOLive

January 26-27, 2026 | Rome

Register interest: info@betaglue.com


Gianluca
De Danieli
Head of Clinical Development

What we’re building

News

Discover the latest from our lab and clinic
BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer
Website Launch

BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer

Milan, September 22, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid…

Read more
1200 800 Betaglue® Therapeutics
BetaGlue® Announces ASCO Abstract Publication of the use of YntraDose® in an Advanced Large Animal Model of Pancreatic Cancer

BetaGlue® Announces ASCO Abstract Publication of the use of YntraDose® in an Advanced Large Animal Model of Pancreatic Cancer

Milan, May 27th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®,…

Read more
1201 800 Betaglue® Therapeutics
BetaGlue® Completes Exclusive Global Agreement With ArtivionTM Securing Supply Of BioGlue® For The Manufacture Of BetaGlue’s YntraDose® Oncology Platform
YntraDose Glue Syringe Size S

BetaGlue® Completes Exclusive Global Agreement With ArtivionTM Securing Supply Of BioGlue® For The Manufacture Of BetaGlue’s YntraDose® Oncology Platform

Milan, February 20th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®,…

Read more
1200 800 Betaglue® Therapeutics